Last reviewed · How we verify
VTS-K
VTS-K is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.6.
VTS-K is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.6. Used for Treatment of focal epilepsy.
At a glance
| Generic name | VTS-K |
|---|---|
| Also known as | Ketamine + Aspirin |
| Sponsor | Maimonides Medical Center |
| Drug class | sodium-activated potassium channel inhibitor |
| Target | Nav1.6 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting Nav1.6, VTS-K reduces the excitability of neurons, which can help alleviate symptoms of certain neurological disorders. This mechanism of action is thought to be responsible for the therapeutic effects of VTS-K, although the exact mechanisms underlying its clinical benefits are still being studied.
Approved indications
- Treatment of focal epilepsy
Common side effects
- Dizziness
- Headache
- Nausea
Key clinical trials
- Prolonged Manual Ventilation Simulation (NA)
- Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression (PHASE4)
- Analgesic Efficacy of Orally Administered VTS-K for Pain Management
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VTS-K CI brief — competitive landscape report
- VTS-K updates RSS · CI watch RSS
- Maimonides Medical Center portfolio CI